Literature DB >> 16740703

Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci.

Greg Cohen1, Reba Mustafi, Anusara Chumsangsri, Nathaniel Little, Jeff Nathanson, Sonia Cerda, Sujatha Jagadeeswaran, Urszula Dougherty, Loren Joseph, John Hart, Lisa Yerian, Maria Tretiakova, Weihua Yuan, Piotr Obara, Sharad Khare, Frank A Sinicrope, Alessandro Fichera, Gerry R Boss, Robert Carroll, Marc Bissonnette.   

Abstract

Aberrant crypt foci (ACF) are collections of abnormal colonic crypts with heterogeneous molecular and pathologic characteristics. Large and dysplastic ACF are putative precursors of colon cancer with neoplastic risk related to increased proliferation. In this study, we examined the role of epidermal growth factor receptor (EGFR) signaling in regulating ACF proliferation. Using magnification chromoendoscopy, we collected large ACF with endoscopic features of dysplasia and separately biopsied adjacent mucosa. Transcript levels were measured by real-time PCR, proteins were assessed by Western blotting, and levels were expressed as fold changes of adjacent mucosa. K-ras and B-Raf mutations were assessed by PCR and Ras activation by the ratio Ras-GTP / (Ras-GTP + Ras-GDP). At the RNA level, 38% of ACF were hyperproliferative, with proliferating cell nuclear antigen (PCNA) mRNA >/=2-fold of adjacent mucosa. Hyperproliferative ACF had significantly increased mRNA levels of EGFR (6.0 +/- 1.7-fold), transforming growth factor-alpha (14.4 +/- 5.0-fold), heparin-binding EGF-like growth factor (4.5 +/- 1.4-fold), cyclin D1 (4.6 +/- 0.7-fold), and cyclooxygenase-2 (COX-2; 9.3 +/- 4.2-fold; P < 0.05). At the protein level, 46% of ACF were hyperproliferative (PCNA, 3.2 +/- 1.2-fold). In hyperproliferative ACF, 44% possessed significant increases in four EGFR signaling components: EGFR (9.5 +/- 1.3-fold), phosphoactive ErbB2 (2.6 +/- 0.4-fold), phosphoactive extracellular signal-regulated kinase (3.7 +/- 1.1-fold), and cyclin D1 (3.4 +/- 0.8-fold; P < 0.05). Ras was activated in 46% of ACF (3.2 +/- 0.4-fold; P < 0.05), but K-ras mutations were present in only 7% of ACF. In contrast to COX-2 mRNA, the protein was not increased in hyperproliferative ACF. In summary, we have shown that ACF with up-regulated PCNA possess increased EGFR signaling components that likely contribute to the enhanced proliferative state of dysplastic-appearing ACF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740703     DOI: 10.1158/0008-5472.CAN-05-0308

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer.

Authors:  James M Bugni; Leina Al- Rabadi; Kevin Jubbal; Iordanis Karagiannides; Gregory Lawson; Charalabos Pothoulakis
Journal:  Int J Cancer       Date:  2011-11-17       Impact factor: 7.396

2.  TNF-α induces upregulation of EGFR expression and signaling in human colonic myofibroblasts.

Authors:  James Yoo; Citlali Ekaterina Rodriguez Perez; Wenxian Nie; Robert A Edwards; James Sinnett-Smith; Enrique Rozengurt
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-02-02       Impact factor: 4.052

3.  Epidermal growth factor receptor inhibits colitis-associated cancer in mice.

Authors:  Philip E Dubé; Fang Yan; Shivesh Punit; Nandini Girish; Steven J McElroy; M Kay Washington; D Brent Polk
Journal:  J Clin Invest       Date:  2012-07-09       Impact factor: 14.808

4.  Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.

Authors:  Ramesh K Wali; Dhananjay P Kunte; Jennifer L Koetsier; Marc Bissonnette; Hemant K Roy
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

5.  Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein.

Authors:  Vivek Venkataramani; Christian Rossner; Lara Iffland; Stefan Schweyer; Irfan Y Tamboli; Jochen Walter; Oliver Wirths; Thomas A Bayer
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

6.  Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer.

Authors:  Elizabeth M Poole; Karen Curtin; Li Hsu; Richard J Kulmacz; David J Duggan; Karen W Makar; Liren Xiao; Christopher S Carlson; Martha L Slattery; Bette J Caan; John D Potter; Cornelia M Ulrich
Journal:  Int J Mol Epidemiol Genet       Date:  2011-12-03

7.  Aneuploid human colonic epithelial cells are sensitive to AICAR-induced growth inhibition through EGFR degradation.

Authors:  P Ly; S B Kim; A A Kaisani; G Marian; W E Wright; J W Shay
Journal:  Oncogene       Date:  2012-08-13       Impact factor: 9.867

Review 8.  Antidepressant fluoxetine and its potential against colon tumors.

Authors:  Helga Stopper; Sergio Britto Garcia; Ana Maria Waaga-Gasser; Vinicius Kannen
Journal:  World J Gastrointest Oncol       Date:  2014-01-15

9.  Acetylcholine-induced activation of M3 muscarinic receptors stimulates robust matrix metalloproteinase gene expression in human colon cancer cells.

Authors:  Guofeng Xie; Kunrong Cheng; Jasleen Shant; Jean-Pierre Raufman
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-02-12       Impact factor: 4.052

10.  Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.

Authors:  Jorge-Shmuel Delgado; Reba Mustafi; Jason Yee; Sonia Cerda; Anusara Chumsangsri; Urszula Dougherty; Lev Lichtenstein; Alessandro Fichera; Marc Bissonnette
Journal:  Dig Dis Sci       Date:  2008-05-30       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.